With a distinguished background in advancing cytopathology practices through research, artificial intelligence (AI) innovations, and thought leadership in the medical community, Dr. Chong’s expertise will contribute across various critical areas for ROSEAId, including scientific review of impactful research proposals, clinical care advisement, patients and caregiver education, selection of new research initiatives, and guidance on ongoing project assessments.

Dr. Chong is currently an Associate Professor at The Catholic University of Korea. He serves as the Scientific Program Director of The Korean Society for Cytopathology (KSC) and has led the KSC Quality Improvement Program for the past four years. He is recognized for his research, leadership and contributions to AI applications in medicine, including his work on the consensus paper for pathologic practice using digital pathology.

"Our team is delighted to welcome Dr. Chong to our Scientific Medical Advisory Board," said Eli Zukovsky, CTO and Founder of ROSEAId. "His expertise in digital pathology and commitment to advancing healthcare through innovation makes him a valuable addition to our leadership team. We look forward to working with Dr. Chong to fulfill our mission of improving patient care and driving better outcomes through the latest advancements in digital pathology solutions."

About Dr. Yosep Chong:
Dr. Chong recently completed a visiting scholarship program at the University of Utah in the Computational Pathology Lab. He is currently involved in multiple national projects in Korea, including DEEP: URO, CoDiPAI, STANDBAI, DEEP: CRC, and PROMISE-P, and international collaborations with companies and technology universities in Korea, the U.S., Sweden, India, Japan, Taiwan, and China. His work focuses on developing deep learning algorithms for various medical diseases, including colorectal, prostate, skin, renal, and gastrointestinal cancers, including various cytopathology samples, especially urine and thyroid cytology. Additionally, Dr. Chong has been involved in developing guidelines and validation procedures for AI-based medical devices for Ministry of Food and Drug Safety (Korea).

About ROSEAId:
ROSEAId is a leading provider of AI-powered solutions for pathologists, scientists, and healthcare professionals for cancer detection and treatment efficacy. Our platforms enable real-time, accurate quantitative evaluation of tissues using advanced artificial intelligence (AI) algorithms and knowledge engineering supporting remote analysis, collaboration, and streamlined processes for better outcomes. Our Multi-Modal Large Language Foundational Model (MLLFM) transforms the way data is analyzed and simulated for faster and more profound investigation into the intricacies of biological complexities and associations.

Media contacts: Email: [email protected]
For more information visit https://roseaid.com.
Follow us on https://www.linkedin.com/company/roseaid/
###